The Mayo Clinic criteria for mild cognitive impairment (MCI)21

are less precise and their formulation has changed with time (Table II, page 66) .21, 25-33 As a consequence, the heading ”MCI“ covers highly variable diagnostic methodologies, hampering comparisons of studies from different research teams. Table II. Definition and criteria for mild cognitive impairment (MCI).21, 25-26 ADL, activities of daily living; CDR, Clinical Dementia Inhibitors,research,lifescience,medical Rating; DSM-III-R, Diagnostic and Statistical Manual of Mental Health Disorders. 3rd ed, revised; MMSE, Mini-Mental State Examination. … These different concepts and criteria have seldom been compared in the same population. In a recent, study,34 111 subjects with informant, evidence of cognitive decline Inhibitors,research,lifescience,medical were classified as AAMI (n=37, 33.3%) after clinical assessment. When AACD criteria were also applied, they were fulfilled by 39 subjects (35.1 %), including 20 (54%)” of the AAMIs. Moreover, as illustrated in Figure 1 (seepage 66), the

cognitive profiles of subjects with AACD or AAMI were different, with 35.9% Inhibitors,research,lifescience,medical of AACDs vs 27% of AAMIs impaired in the memory and learning domain according to AACD criteria (ie, at least 1 SD below age-appropriate norms), and 35.9% AACDs vs 18.9% AAMls impaired in more than one cognitive domain.34 Figure 1. Cognitive profile in age-associated memory impairment (AAMI) and aging-associated cognitive decline (AACD) subjects, according to the data in reference 34. Memory: according to AACD criteria (at least 1 SD below age-appropriate norms). IMI, isolated memory … As expected according to their individual definitions and goals, the AAMI and AACD concepts only modestly overlap one another; the latter captures

a more severe Inhibitors,research,lifescience,medical impairment. Inhibitors,research,lifescience,medical In the Canadian Study of Health and Aging, specific criteria were applied in subjects classified as CIND.22 Sixty-five percent did not meet any of them; none met the AAMI criteria of Bradford and LaRue.16 When inclusion criteria were applied alone, 8.1% fitted the criteria for AAMI. 5.9% for ACMI, 7.4 % for LLF, and 34% AACD; after applying Resveratrol exclusion criteria, these figures dropped to 1.2 % (AAMI), 0.9 % (ACMI), 0 % (LLF), and 13 % (AACD). These data highlight the importance of exclusion criteria resulting from comprehensive clinical evaluation. Only 24% of those meeting one set of criteria also met one other or more (19.2 % met two, 3.8 % three, and 0.8 % four), suggesting that the different sets of criteria are mutually exclusive. In a sample of 60 – to 64 – year-old Alectinib in vitro healthy people, 35 13.5% met criteria for AAMI, 6.5 % for ACMI, 1.5 % for LLF, and 23.5 % for AACD. Among subjects with AAMI, 22 % met the criteria for ACMI, 11 % for LLF, and 63 % for AACD. All the LLF subjects also fulfilled criteria for both AAMI and AACD. Together these results are not very surprising.